Tonix Pharmaceuticals Holding Corp. (TNXP)
5.17
+0.04
(+0.78%)
USD |
NASDAQ |
Oct 23, 16:00
5.31
+0.14
(+2.71%)
After-Hours: 20:00
Tonix Pharmaceuticals Enterprise Value : -88.14M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -88.14M |
| October 22, 2026 | -88.82M |
| October 21, 2026 | -83.78M |
| October 20, 2026 | -77.90M |
| October 19, 2026 | -78.74M |
| October 16, 2026 | -73.53M |
| October 15, 2026 | -67.15M |
| October 14, 2026 | -67.49M |
| October 13, 2026 | -72.02M |
| October 12, 2026 | -63.46M |
| October 09, 2026 | -52.38M |
| October 08, 2026 | -52.71M |
| October 07, 2026 | -48.18M |
| October 06, 2026 | -45.74M |
| October 05, 2026 | -39.45M |
| October 02, 2026 | -25.34M |
| October 01, 2026 | -19.97M |
| September 30, 2026 | -11.40M |
| September 29, 2026 | -12.91M |
| September 28, 2026 | -8.716M |
| September 25, 2026 | -9.388M |
| September 24, 2026 | -12.07M |
| September 23, 2026 | -3.007M |
| September 22, 2026 | 2.870M |
| September 21, 2026 | 5.054M |
| Date | Value |
|---|---|
| September 18, 2026 | 7.572M |
| September 17, 2026 | 16.81M |
| September 16, 2026 | 22.52M |
| September 15, 2026 | 20.17M |
| September 14, 2026 | 22.01M |
| September 11, 2026 | 24.36M |
| September 10, 2026 | 31.25M |
| September 09, 2026 | 40.49M |
| September 08, 2026 | 46.03M |
| September 04, 2026 | 45.69M |
| September 03, 2026 | 49.55M |
| September 02, 2026 | 49.72M |
| September 01, 2026 | 59.80M |
| August 31, 2026 | 61.81M |
| August 28, 2026 | 53.25M |
| August 27, 2026 | 52.74M |
| August 26, 2026 | 54.09M |
| August 25, 2026 | 54.42M |
| August 24, 2026 | 34.10M |
| August 21, 2026 | 35.78M |
| August 20, 2026 | 33.10M |
| August 19, 2026 | 38.81M |
| August 18, 2026 | 37.63M |
| August 17, 2026 | 37.63M |
| August 14, 2026 | 38.47M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Inovio Pharmaceuticals, Inc. | 45.20M |
| Nektar Therapeutics | 721.90M |
| Heron Therapeutics, Inc. | 164.11M |
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -40.55M |
| Revenue (Quarterly) | 13.54M |
| Total Expenses (Quarterly) | 54.10M |
| EPS Diluted (Quarterly) | -2.438 |
| Gross Profit Margin (Quarterly) | 90.24% |
| Profit Margin (Quarterly) | -299.4% |
| Earnings Yield | -250.2% |
| Normalized Earnings Yield | -250.16 |